- Companies
- Collate
Collate Valuation, Funding & Investors
Collate is valued at $1B as of June 2026.
Last Collate valuation
$1B
Undisclosed stage · Jun 2026
Last Collate funding round
$95M
Undisclosed stage · Jun 2026
Cumulative funding Collate raised
$125M
across 2 funding rounds
Key investors in Collate
Redpoint
Y Combinator
First Round Capital
Conviction Embed
About Collate
Collate is a San Francisco-based platform leveraging artificial intelligence to automate documentation for drug development, medical devices, and diagnostics firms. It generates regulatory submissions, clinical protocols, and quality management documents from concept through commercialization, reducing preparation time by integrating with tools like Veeva and MasterControl. Serving life sciences companies worldwide, Collate ensures compliance with FDA, EMA, and ISO standards while streamlining collaborative authoring. Launched in 2022, the platform processes thousands of documents annually for biotech and medtech innovators.
Founded
2025
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Valuation
$1B (Jun 2026)
Collate Valuation
Collate is currently valued at $1B, based on its undisclosed-stage round in June 2026.
The $95M round was led by Redpoint.
Collate's valuation has grown 10x from $100M at its seed round in January 2025 to $1B in June 2026, across 2 priced rounds.
Collate valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jun 2026 | Undisclosed stage | $1B |
| Jan 2025 | Seed | $100M |
Collate Funding History
Collate has raised a total of $125M across 2 funding rounds.
Collate's first fundraising round was a $30M seed round in January 2025. The most recent completed round was a $95M undisclosed-stage round in June 2026.
Collate funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jun 2026 | Undisclosed stage | Redpoint (lead) | $95M | $1B | Redpoint Ventures led Collate’s June 2026 financing with $95M at an approximately $1B valuation, bringing total funding to $125M. The round was positioned around scaling Collate’s AI automation for life sciences paperwork, including regulatory submissions, clinical trial documentation, and compliance filings. Earlier reporting indicates Collate had previously raised $40M across two rounds, including a $30M seed in January 2025 and a $10M Series A in July 2025, with Redpoint Ventures listed among the seed investors. Collate operates as a life sciences AI company focused on automating documentation workflows for pharmaceutical and biotech customers. |
| Jan 2025 | Seed | Redpoint (lead); Conviction Embed; First Round Capital; Y Combinator | $30M | $100M | Collate is a biotech AI startup founded and led by Surbhi Sarna, an accomplished serial entrepreneur who previously founded nVision Medical, which Boston Scientific acquired for $275 million in 2018. The company focuses on automating labor-intensive documentation processes in the life sciences industry using large language models and AI. Collate's platform streamlines paperwork for diagnostic, medical device, and drug development companies, aiming to accelerate research and development, optimize preclinical and clinical trials, enhance quality management, and reduce time to market for new drugs, diagnostics, and devices. In January 2025, Collate emerged from stealth with a $30 million seed round led by Redpoint Ventures, with participation from First Round Capital, Conviction Partners, and Y Combinator. The round valued the company at over $100 million post-money. Satish Dharmaraj of Redpoint emphasized the long-term potential of the platform, noting its low-velocity, high-contract-value sales model would create sticky, value-generating relationships with enterprise customers in life sciences. The funding will support product development and market expansion as Collate aims to automate a critical but underserved workflow across the industry. |
Who has invested in Collate?
4 investors have backed Collate across its funding rounds, including Redpoint, Y Combinator, First Round Capital and Conviction Embed.
Lead investors include Redpoint.
Collate Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Jan 2025 | ||
| 1 | Participant | Jan 2025 | ||
This data is available for Pro users. Sign up to see all 4 Collate investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialCollate Competitors
Collate competitors include listed companies like Arcs Co and Appier Group, and private ones like Iambic, Altana, Augury and Beamery.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $4B | $185M | $1.3B | 0.2x | ||
| Private | - | - | $600M | - | ||
| Private | - | $564M | $1B | - | ||
| Private | $100M | - | $1B | - | ||
| Private | - | - | $1B | - | ||
| Publicly listed | $281M | $44M | $1B | 2.9x |
Collate Public Comps
Collate is still privately-owned, but its public comps include Appier Group, Rackspace, Extreme Vision, iFLYHealth, Rezolve AI, Beijing CTJ Info Tech, Optasia, ODDITY Tech, SEEGENE and Bide Pharmatech Co.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $281M | $44M | 3.4x | 2.9x | 21.6x | 15.7x | |||
| $2.7B | $244M | 1.5x | 1.6x | 17.1x | 15.0x | |||
| $44M | ($6M) | 22.8x | 11.6x | (163.7x) | - | |||
| $136M | ($7M) | 7.7x | 6.2x | (150.8x) | (144172.5x) | |||
| $47M | ($109M) | 23.3x | 4.0x | (10.0x) | (19.3x) | |||
| $123M | $13M | 5.3x | 4.9x | 51.3x | 34.6x | |||
| $265M | $79M | 4.3x | 3.6x | 14.5x | 9.1x | |||
| $810M | $131M | 1.5x | 1.8x | 9.6x | 18.3x | |||
This data is available for Pro users. Sign up to see all Collate competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Collate
| When was Collate founded? | Collate was founded in 2025. |
| Where is Collate headquartered? | Collate is headquartered in San Francisco, CA, United States. |
| Is Collate publicly listed? | No, Collate is a private, VC-backed company. |
| What is Collate's valuation? | Collate was last valued at $1B in its undisclosed-stage round in June 2026. |
| How much funding has Collate raised? | Collate has raised $125M across 2 funding rounds. |
| What was Collate's last funding round? | Collate's last funding round was a $95M undisclosed-stage round in June 2026, led by Redpoint. |
| Who are Collate's investors? | Collate's investors include Redpoint, Conviction Embed, First Round Capital and Y Combinator. |
| Which companies are comparable to Collate? | Companies comparable to Collate include Arcs Co, Iambic, Altana, Augury, Beamery and Appier Group. |
See companies similar to Collate
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




